Previous 10 | Next 10 |
Seres Therapeutics (NASDAQ: MCRB ) +266% on success of lead drug in C. diff study. More news on: Seres Therapeutics, Inc., Trevena, Inc., Hoth Therapeutics, Inc., Stocks on the move, , Read more ...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Volatility watch: Some of the volatility names to watch include Nokia (NYSE: NOK ) , Kroger (NYSE: KR ) , Alexandria Real Estate (NYSE: ARE ) and Dave & Buster's Entertainment (NASDAQ: PLAY ) with short interest positions on the rise. Traders are also taking dead aim at retail n...
DEER PARK, Ill., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report second quarter 2020 financial and operating results on Wedn...
Eton Pharmaceuticals (NASDAQ: ETON ) announces that it has submitted a marketing application to the FDA seeking approval of zonisamide oral suspension (previously known as ET-104) for the treatment of partial seizures in epilepsy patients. More news on: Eton Pharmaceuticals, Inc., Heal...
- Application Submitted for the Treatment of Partial Seizures in Epilepsy Patients - Eton’s Patent-Pending Product Addresses Significant Unmet Need for a Liquid Formulation of Zonisamide - Application is Eton’s Sixth Drug Application Under FDA Review DEER PARK, Ill., J...
-Granted Orphan Drug Designation by the FDA for the Treatment of Methanol Poisoning -Since the Start of COVID-19, the FDA has Recalled More Than 75 Contaminated Hand Sanitizers Due to Risk of Methanol Poisoning -DS-100 is Eton’s Fifth Drug Application Under FDA Review and Second...
Eton Pharmaceuticals, Inc. (ETON) Q1 2020 Earnings Conference Call May 14, 2020, 4:30 PM ET Company Participants David Krempa - VP, Business Development Sean Brynjelsen - Chief Executive Officer Wilson Troutman - Chief Financial Officer Paul Stickler - Senior Vice President o...
Eton Pharmaceuticals (NASDAQ: ETON ): Q1 GAAP EPS of -$0.50 misses by $0.28 . More news on: Eton Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
DEER PARK, Ill., May 14, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today reported financial results for the first quarter ended March 31, 2020 and provided an upda...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
Eton Pharmaceutcials Inc. Website:
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innov...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13 th straight quarter of sequential product sales growth • Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...